Study of Specific Allergen Immunotherapy in Grass Pollen Allergic Subjects by Epicutaneous Allergen Administration

Launched by UNIVERSITY OF ZURICH · Jul 18, 2008

Keywords

ClinConnect Summary

No description provided

Gender

ALL

Eligibility criteria

• Inclusion criteria:
• • Written informed consent
• • History of grass pollen allergic rhinitis
• • Male and female between 18 years to 65 years
• • Positive skin-prick test to grass pollen
• • Positive conjunctival provocation test
• Exclusion criteria:
• • Eczematous skin lesions on the upper arms
• • Perennial allergic rhinitis
• • Symptoms of infectious disease with rhinitis in between the last 2 weeks
• • Surgical intervention in between the last 30 days
• • Pregnancy or nursing
• • History of HIV or AIDS
• • History of mastocytosis (cutaneous or systemic)
• • History of significant cardiovascular disease
• • Hypertension (blood pressure \> 160 / 95)
• • History of significant pulmonary, renal and/or hepatic disease
• • History of significant hematological disorder
• • Moderate or severe asthma
• • History of malignancy
• • History of neurological or psychiatric disease
• • History of autoimmune disease
• • Antihistamines with longed half-lives in the last week
• • Systemic or topical steroids for 5 days
• • Active infectious disease
• * Contraindicated medications:
• • immunosuppressive agents
• • Betablockers
• • ACE-inhibitors, AT 2 Antagonists
• • tricyclic antidepressants
• • daily use of Beta-agonists or steroid inhalers
• • Participation in another clinical trial /study at the moment or within the last 60 days